Companies › Legend Biotech USA
2 active drug programs in 2 registered trials: 2 Phase 1; Oncology, Gastroenterology; next expected readout Dec 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| LB1908 anti-CLDN18.2 CAR-T cell therapy | CLDN18 | Phase 1 | Gastric Cancer | Dec 2027 |
| LB2102 DLL3-directed autologous chimeric antigen receptor T-cell (CAR-T) therapy | – | Phase 1 | Small Cell Lung Cancer Extensive Stage | Dec 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05680922 | LB2102 | Phase 1 | Small Cell Lung Cancer Extensive Stage | Oncology | Dec 2027 |
| NCT05539430 | LB1908 | Phase 1 | Gastric Cancer | Gastroenterology | Dec 2027 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.